Healthcare acquired infections and vaccines - the profile determines everything. Published 28th April 2010
Healthcare acquired infections (HAIs) continue to be a major concern to all hospital stakeholders. Beyond increased infection control and stewardship of antibiotic use, the vaccine industry is taking the possibility of further interventions seriously with major programs now in
advanced clinical development. VacZine Analytics has analyzed the commercial viability of new "nosocomial vaccines" and discuss the latest issues.
PREMIUMThis article is available only on a "pay per view" basis or to purchasers of MarketVIEW: Staphylococcus aureus or Pseudomonas aureginosa vaccines (CAT Nos: VAMV002 & VAMV010)